Daniel M. Anderson, MD, MPH
Principal Investigator, Metro-Minnesota Community Oncology Research Consortium

Clinical Profile 

About

Affiliations/other offices held: Assistant Professor, Department of Hematology, Oncology and Transplantation, University of Minnesota.

Joined the Institute: 2003

Education and training: MD, University of Minnesota; residency in internal medicine, Hennepin County Medical Center; fellowship in hematology/oncology, University of Minnesota; MPH in epidemiology, University of Minnesota.

Overview/research interests: Dr. Anderson serves as the Principal Investigator for the Metro-Minnesota Community Oncology Research Consortium. Additionally, he is a co-chair of the Community Oncology Committee at the Alliance for Clinical Trials in Oncology. He became interested in working with people with cancer because of the unique relationships he has developed with them. He also enjoys the intellectual challenge of working with patients who have blood and clotting disorders. He is a member of the American Society of Hematology, American Society of Clinical Oncology, American Association for Cance

Affiliation

positions

  • Principal Investigator, Metro-Minnesota Community Oncology Research Consortium, Cancer Research Center 2003 -
  • Publications While At HealthPartners

    selected publications

    Journal Article
  • Feasibility of structuring electronic health record data to facilitate real-world data research: ICAREdata methods applied to multicenter cancer clinical trials
    Cancer. 2025
  • PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)
    Journal of Clinical Oncology. 2024
  • Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trial
    The oncologist. 2024
  • Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
    Commun Med (Lond). 2023
  • Validation of immunotherapy response score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit
    Cancer Res Commun. 2023
  • Contact

    full name

  • Daniel M. Anderson, MD, MPH
  • located in facility

    Quick Info

    Publications

    Collaboration

    More Info